These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 38214675)
1. Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double-blind, placebo-controlled trial. Fayoux P; Dinomais M; Shaw H; Villain F; Schwartz D; Rondeau S; Letellier G; Auvin S Dev Med Child Neurol; 2024 Jul; 66(7):910-918. PubMed ID: 38214675 [TBL] [Abstract][Full Text] [Related]
2. Randomised, double-blind, placebo-controlled trial of glycopyrronium in children and adolescents with severe sialorrhoea and neurodisabilities: protocol of the SALIVA trial. Fayoux P; Dinomais M; Shaw H; Probert N; Villain F; Pouchain D; Texier N; Auvin S BMJ Paediatr Open; 2023 May; 7(1):. PubMed ID: 37156563 [TBL] [Abstract][Full Text] [Related]
3. Glycopyrronium for severe drooling in children. Drug Ther Bull; 2017 Aug; 55(8):93-96. PubMed ID: 28808084 [TBL] [Abstract][Full Text] [Related]
4. Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Parr JR; Todhunter E; Pennington L; Stocken D; Cadwgan J; O'Hare AE; Tuffrey C; Williams J; Cole M; Colver AF Arch Dis Child; 2018 Apr; 103(4):371-376. PubMed ID: 29192000 [TBL] [Abstract][Full Text] [Related]
5. The drooling reduction intervention trial (DRI): a single blind trial comparing the efficacy of glycopyrronium and hyoscine on drooling in children with neurodisability. Parr JR; Weldon E; Pennington L; Steen N; Williams J; Fairhurst C; O'Hare A; Lodh R; Colver A Trials; 2014 Feb; 15():60. PubMed ID: 24533890 [TBL] [Abstract][Full Text] [Related]
6. Glycopyrrolate for chronic drooling in children. Eiland LS Clin Ther; 2012 Apr; 34(4):735-42. PubMed ID: 22445330 [TBL] [Abstract][Full Text] [Related]
7. Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions. Garnock-Jones KP Paediatr Drugs; 2012 Aug; 14(4):263-9. PubMed ID: 22646067 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940 [TBL] [Abstract][Full Text] [Related]
9. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448 [TBL] [Abstract][Full Text] [Related]
10. The when, why, and how of using glycopyrronium to diminish drooling in children with neurodevelopmental disabilities: Implications for clinical practice. Orriëns LB; van der Burg JJW; van den Hoogen FJA; Willemsen MAAP; van Hulst K; Erasmus CE Eur J Paediatr Neurol; 2024 Jul; 51():24-31. PubMed ID: 38776696 [TBL] [Abstract][Full Text] [Related]
11. Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy. Dias BLS; Fernandes AR; Maia HS Arq Neuropsiquiatr; 2017 May; 75(5):282-287. PubMed ID: 28591387 [TBL] [Abstract][Full Text] [Related]
12. Glycopyrrolate for drooling in children with medical complexity under three years of age. Lovardi E; De Ioris MA; Lettori D; Geremia C; Staccioli S; Bella GD; Scrocca R; Scarselli A; Aversa M; De Peppo F; Campana A; Castelli E Ital J Pediatr; 2022 Jan; 48(1):2. PubMed ID: 34998418 [TBL] [Abstract][Full Text] [Related]
13. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058 [TBL] [Abstract][Full Text] [Related]
14. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD. Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504 [TBL] [Abstract][Full Text] [Related]